| 规格: | 98% |
| 分子量: | 547.78 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
Background:
Cedirogant (ABBV-157) is an orally active RORγt inverse agonist. Cedirogant can be used for psoriasis research[1][2].
The transcription factor retinoic acid-related orphan receptor gamma t (RORγt) has been identified as the master regulator of TH17 cell differentiation and IL-17/22 production and is therefore an attractive target for the treatment of inflammatory diseases. Cedirogant (ABBV-157) has the potential for chronic plaque psoriasis research[1].
[1]. Elena Campione, et al. Experimental Pharmacological Management of Psoriasis. J Exp Pharmacol. 2021 Jul 26;13:725-737.
[2]. Christian Gege. Retinoic acid-related orphan receptor gamma t (RORγt) inverse agonists/antagonists for the treatment of inflammatory diseases - where are we presently• Expert Opin Drug Discov. 2021 Jul 7;1-19.
m.cnreagent.com